title: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
abstract: Treatment of allergic disease by decreasing circulating IgE with anti-IgE Abs is currently under clinical study. Based on previous unrelated studies, it appeared likely that Fc(epsilon)RI expression on basophils and mast cells might also be regulated by levels of circulating IgE Ab. Therefore, the expression of IgE and Fc(epsilon)RI on human basophils was examined in 15 subjects receiving humanized anti-IgE mAb intravenously. Treatment with the anti-IgE mAb decreased free IgE levels to 1% of pretreatment levels and also resulted in a marked down-regulation of Fc(epsilon)RI on basophils. Median pretreatment densities of Fc(epsilon)RI were approximately 220,000 receptors per basophil and after 3 mo of treatment, the densities had decreased to a median of 8,300 receptors per basophil. Flow cytometric studies, conducted in parallel, showed similar results and also showed in a subset of 3 donors that receptors decreased with a t1/2 of approximately 3 days. The responsiveness of the cells to IgE-mediated stimulation using anti-IgE Ab was marginally decreased (approximately 40%) while the response of the same cells to stimulation with dust mite Ag, Dermatophagoides farinae, was reduced by approximately 90%. One possible explanation for these results is that Fc(epsilon)RI density is directly or indirectly regulated by plasma-free IgE levels.
authors.affiliation: Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA. dmacglas@welchlink.welch.jhu.edu
authors.forename: D W
authors.initials: DW
authors.lastname: MacGlashan
authors.forename: B S
authors.initials: BS
authors.lastname: Bochner
authors.forename: D C
authors.initials: DC
authors.lastname: Adelman
authors.forename: P M
authors.initials: PM
authors.lastname: Jardieu
authors.forename: A
authors.initials: A
authors.lastname: Togias
authors.forename: J
authors.initials: J
authors.lastname: McKenzie-White
authors.forename: S A
authors.initials: SA
authors.lastname: Sterbinsky
authors.forename: R G
authors.initials: RG
authors.lastname: Hamilton
authors.forename: L M
authors.initials: LM
authors.lastname: Lichtenstein
mesh_terms: D000328:Adult; D000485:Allergens / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001491:Basophils / Q000276:immunology*; D015536:Down-Regulation; D005260:Female; D006636:Histamine Release; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007073:Immunoglobulin E / Q000008:administration & dosage* / Q000378:metabolism; D007167:Immunotherapy; D008297:Male; D017455:Receptors, IgE / Q000378:metabolism*
chemical_list: D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D017455:Receptors, IgE; D007073:Immunoglobulin E